{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:17:25Z","timestamp":1790219845050,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.pharmthera.2021.107918","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T10:44:04Z","timestamp":1624445044000},"page":"107918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["TLR4 biased small molecule modulators"],"prefix":"10.1016","volume":"228","author":[{"given":"Cong","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2021.107918_bb0005","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"18488","article-title":"Discovery of \u03b2-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy","volume":"108","author":"Allen","year":"2011"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0952-7915(99)00046-1","article-title":"Tlr4: Central component of the sole mammalian LPS sensor","volume":"12","author":"Beutler","year":"2000","journal-title":"Current Opinion in Immunology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1152\/physiolgenomics.00128.2004","article-title":"The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades","volume":"19","author":"Bj\u00f6rkbacka","year":"2004","journal-title":"Physiological Genomics"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4062\/biomolther.2016.165","article-title":"Biased G protein-coupled receptor signaling: New player in modulating physiology and pathology","volume":"25","author":"Bologna","year":"2017","journal-title":"Biomolecules & Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/B978-0-12-404717-4.00003-2","article-title":"Immunopharmacology of lipid a mimetics","volume":"66","author":"Bowen","year":"2013","journal-title":"Advances in Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0030","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2001963","article-title":"Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist","volume":"5","author":"Bowen","year":"2012","journal-title":"Science Signaling"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/1047-8477(90)90093-R","article-title":"Phase diagram of lipid a from Salmonella Minnesota and Escherichia coli rough mutant lipopolysaccharide","volume":"105","author":"Brandenburg","year":"1990","journal-title":"Journal of Structural Biology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0040","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bbi.2017.08.012","article-title":"Innate immune signaling in the ventral tegmental area contributes to drug-primed reinstatement of cocaine seeking","volume":"67","author":"Brown","year":"2018","journal-title":"Brain, Behavior, and Immunity"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0045","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1128\/AAC.39.7.1462","article-title":"Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia","volume":"39","author":"Bucklin","year":"1995","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0050","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bbi.2018.05.021","article-title":"TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia","volume":"73","author":"Burfeind","year":"2018","journal-title":"Brain, Behavior, and Immunity"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0055","doi-asserted-by":"crossref","first-page":"31982","DOI":"10.1074\/jbc.M109.046383","article-title":"Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid a","volume":"284","author":"Cekic","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0060","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/syn.21555","article-title":"Naloxone can act as an analgesic agent without measurable chronic side effects in mice with a mutant mu-opioid receptor expressed in different sites of pain pathway","volume":"66","author":"Chou","year":"2012","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0065","doi-asserted-by":"crossref","first-page":"10689","DOI":"10.1074\/jbc.274.16.10689","article-title":"Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction","volume":"274","author":"Chow","year":"1999","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0070","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1128\/IAI.73.5.3044-3052.2005","article-title":"Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge","volume":"73","author":"Cluff","year":"2005","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0075","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1128\/MCB.02098-07","article-title":"Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated NF-kappaB activation","volume":"28","author":"Conze","year":"2008","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0080","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nm.4262","article-title":"Loss of \u03bc opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia","volume":"23","author":"Corder","year":"2017","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0085","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1126\/science.1112304","article-title":"Achieving stability of lipopolysaccharide-induced NF-kappaB activation","volume":"309","author":"Covert","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0090","doi-asserted-by":"crossref","first-page":"36560","DOI":"10.1074\/jbc.M506831200","article-title":"Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation","volume":"280","author":"Cusson-Hermance","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0165-5728(95)00083-E","article-title":"Modulatory effects of [Met5]-enkephalin on interleukin-1 beta secretion from microglia in mixed brain cell cultures","volume":"62","author":"Das","year":"1995","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/35092578","article-title":"Mal (MyD88-adapter-like) is required for toll-like receptor-4 signal transduction","volume":"413","author":"Fitzgerald","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0105","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1084\/jem.20031023","article-title":"LPS-TLR4 signaling to IRF-3\/7 and NF-kappaB involves the toll adapters TRAM and TRIF","volume":"198","author":"Fitzgerald","year":"2003","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0110","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1021\/cn200128x","article-title":"Discovery of small molecule kappa opioid receptor agonist and antagonist Chemotypes through a HTS and hit refinement strategy","volume":"3","author":"Frankowski","year":"2012","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0115","first-page":"92","article-title":"Different dimerisation mode for TLR4 upon endosomal acidification?","volume":"37","author":"Gangloff","year":"2012","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cellsig.2007.08.009","article-title":"IRAK1: A critical signaling mediator of innate immunity","volume":"20","author":"Gottipati","year":"2008","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0125","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ni777","article-title":"Human toll-like receptor 4 recognizes host-specific LPS modifications","volume":"3","author":"Hajjar","year":"2002","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0130","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/s41467-021-22731-x","article-title":"Structural studies of phosphorylation-dependent interactions between the V2R receptor and arrestin-2","volume":"12","author":"He","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0135","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ni0901-835","article-title":"TIRAP: An adapter molecule in the toll signaling pathway","volume":"2","author":"Horng","year":"2001","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0140","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1523\/JNEUROSCI.0684-12.2012","article-title":"Opioid activation of toll-like receptor 4 contributes to drug reinforcement","volume":"32","author":"Hutchinson","year":"2012","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1460-9568.2008.06321.x","article-title":"Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4)","volume":"28","author":"Hutchinson","year":"2008","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bbi.2009.08.004","article-title":"Evidence that opioids may have toll-like receptor 4 and MD-2 effects","volume":"24","author":"Hutchinson","year":"2010","journal-title":"Brain, Behavior, and Immunity"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0155","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4049\/jimmunol.0900460","article-title":"MyD88 and type I interferon receptor-mediated chemokine induction and monocyte recruitment during listeria monocytogenes infection","volume":"183","author":"Jia","year":"2009","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0160","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.cell.2006.03.047","article-title":"Phosphoinositide-mediated adaptor recruitment controls toll-like receptor signaling","volume":"125","author":"Kagan","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0165","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/ni1569","article-title":"TRAM couples endocytosis of toll-like receptor 4 to the induction of interferon-beta","volume":"9","author":"Kagan","year":"2008","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1074-7613(00)80086-2","article-title":"Unresponsiveness of MyD88-deficient mice to endotoxin","volume":"11","author":"Kawai","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0175","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.4049\/jimmunol.167.10.5887","article-title":"Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes","volume":"167","author":"Kawai","year":"2001","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0180","first-page":"296","article-title":"Functional selectivity and biased receptor signaling","volume":"336","author":"Kenakin","year":"2011","journal-title":"The Journal of Pharmacology and ExperimentalTherapeutics"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0185","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.cell.2007.08.002","article-title":"Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran","volume":"130","author":"Kim","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0190","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/09680519030090060901","article-title":"Structural basis for endotoxic and antagonistic activities: Investigation with novel synthetic lipid a analogs","volume":"9","author":"Kusumoto","year":"2003","journal-title":"Journal of Endotoxin Research"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/vaccines5040034","article-title":"TLR4 signaling pathway modulators as potential therapeutics in inflammation and Sepsis","volume":"5","author":"Kuzmich","year":"2017","journal-title":"Vaccines"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0200","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cmet.2018.03.014","article-title":"Evidence that TLR4 is not a receptor for saturated fatty acids but mediates lipid-induced inflammation by reprogramming macrophage metabolism","volume":"27","author":"Lancaster","year":"2018","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0205","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.pain.2005.12.026","article-title":"Chronic pain and genetic background interact and influence opioid analgesia, tolerance, and physical dependence","volume":"121","author":"Liang","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0210","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nature09121","article-title":"Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR\/IL-1R signalling","volume":"465","author":"Lin","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0215","doi-asserted-by":"crossref","first-page":"14335","DOI":"10.1038\/ncomms14335","article-title":"Arrestin-biased AT1R agonism induces acute catecholamine secretion through TRPC3 coupling","volume":"8","author":"Liu","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0220","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1126\/science.1155406","article-title":"Structural basis of toll-like receptor 3 signaling with double-stranded RNA","volume":"320","author":"Liu","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0225","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0885-3924(01)00369-4","article-title":"Low-dose oral naloxone reverses opioid-induced constipation and analgesia","volume":"23","author":"Liu","year":"2002","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0230","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1038\/s41467-020-18433-5","article-title":"DeSiphering receptor core-induced and ligand-dependent conformational changes in arrestin via genetic encoded trimethylsilyl 1 H-NMR probe","volume":"11","author":"Liu","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-61779-160-4_1","article-title":"Refining efficacy: Allosterism and bias in G protein-coupled receptor signaling","volume":"756","author":"Luttrell","year":"2011","journal-title":"Methods in Molecular Biology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0240","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/JLB.3MIR1218-483RR","article-title":"Below the surface: The inner lives of TLR4 and TLR9","volume":"106","author":"Marongiu","year":"2019","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0245","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1126\/science.1138963","article-title":"The vaccine adjuvant monophosphoryl lipid a as a TRIF-biased agonist of TLR4","volume":"316","author":"Mata-Haro","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0250","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1061","article-title":"RIP1 is an essential mediator of toll-like receptor 3-induced NF-kappa B activation","volume":"5","author":"Meylan","year":"2004","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0255","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrmicro1068","article-title":"LPS, TLR4 and infectious disease diversity","volume":"3","author":"Miller","year":"2005","journal-title":"Nature Reviews Microbiology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0260","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/mp.2014.177","article-title":"DAT isn\u2019t all that: Cocaine reward and reinforcement require toll-like receptor 4 signaling","volume":"20","author":"Northcutt","year":"2015","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120583","article-title":"MD-2 determinants of nickel and cobalt-mediated activation of human TLR4","volume":"10","author":"Oblak","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0270","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/nature07830","article-title":"The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex","volume":"458","author":"Park","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0275","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pharmthera.2011.11.001","article-title":"Myeloid differentiation 2 as a therapeutic target of inflammatory disorders","volume":"133","author":"Park","year":"2012","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0280","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/phar.2086","article-title":"The safety and efficacy of Low-dose naltrexone in the Management of Chronic Pain and Inflammation in multiple sclerosis, fibromyalgia, Crohn\u2019s disease, and other chronic pain disorders","volume":"38","author":"Patten","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0285","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.biochem.71.110601.135414","article-title":"Lipopolysaccharide endotoxins","volume":"71","author":"Raetz","year":"2002","journal-title":"Annual Review of Biochemistry"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0290","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1016\/j.vaccine.2020.04.042","article-title":"Dissociation of TRIF bias and adjuvanticity","volume":"38","author":"Richard","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0295","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"6299","article-title":"The myristoylation of TRIF-related adaptor molecule is essential for toll-like receptor 4 signal transduction","volume":"103","author":"Rowe","year":"2006"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0300","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/ni.1919","article-title":"Crucial role for human toll-like receptor 4 in the development of contact allergy to nickel","volume":"11","author":"Schmidt","year":"2010","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0305","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1046\/j.1432-1327.2000.01204.x","article-title":"Biological activities of lipopolysaccharides are determined by the shape of their lipid a portion","volume":"267","author":"Schromm","year":"2000","journal-title":"European Journal of Biochemistry"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0310","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/all.12675","article-title":"MPLA shows attenuated pro-inflammatory properties and diminished capacity to activate mast cells in comparison with LPS","volume":"70","author":"Sch\u00fclke","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0315","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.2402637","article-title":"Structure and function of lipopolysaccharide binding protein","volume":"249","author":"Schumann","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0320","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S1074-7613(03)00330-3","article-title":"Sequential MyD88-independent and -dependent activation of innate immune responses to intracellular bacterial infection","volume":"19","author":"Serbina","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0325","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature12118","article-title":"The TLR4 antagonist Eritoran protects mice from lethal influenza infection","volume":"497","author":"Shirey","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0330","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/med.21318","article-title":"Biased agonism at G protein-coupled receptors: The promise and the challenges--a medicinal chemistry perspective","volume":"34","author":"Shonberg","year":"2014","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0335","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.4049\/jimmunol.1501734","article-title":"Raftlin controls lipopolysaccharide-induced TLR4 internalization and TICAM-1 signaling in a cell type-specific manner","volume":"196","author":"Tatematsu","year":"2016","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0340","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.4049\/jimmunol.175.7.4669","article-title":"Molecular basis of reduced potency of underacylated endotoxins","volume":"175","author":"Teghanemt","year":"2005","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0345","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev.iy.13.040195.002253","article-title":"Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin","volume":"13","author":"Ulevitch","year":"1995","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0350","first-page":"1","article-title":"Functional selectivity and classical concepts of quantitative pharmacology","volume":"320","author":"Urban","year":"2007","journal-title":"The Journal of Pharmacology and ExperimentalTherapeutics"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0355","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.tips.2007.06.006","article-title":"Beta-arrestin-biased ligands at seven-transmembrane receptors","volume":"28","author":"Violin","year":"2007","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0360","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.4049\/jimmunol.181.2.1245","article-title":"Elucidation of the MD-2\/TLR4 interface required for signaling by lipid IVa","volume":"181","author":"Walsh","year":"2008","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0365","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.tips.2018.01.001","article-title":"New insights into modes of GPCR activation","volume":"39","author":"Wang","year":"2018","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0370","series-title":"Microglia in health and disease","first-page":"299","article-title":"Drug addiction","author":"Wang","year":"2014"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0375","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1021\/acschemneuro.9b00225","article-title":"Methamphetamine activates toll-like receptor 4 to induce central immune signaling within the ventral tegmental area and contributes to extracellular dopamine increase in the nucleus Accumbens Shell","volume":"10","author":"Wang","year":"2019","journal-title":"ACS Chemical Neuroscencei"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0380","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/bph.13394","article-title":"Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4","volume":"173","author":"Wang","year":"2016","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0385","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1021\/acs.accounts.9b00631","article-title":"Small-molecule modulators of toll-like receptors","volume":"53","author":"Wang","year":"2020","journal-title":"Accounts of Chemical Research"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0390","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.molmed.2010.11.004","article-title":"Therapeutic potential of \u03b2-arrestin- and G protein-biased agonists","volume":"17","author":"Whalen","year":"2011","journal-title":"Trends in Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0395","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1126\/science.1087262","article-title":"Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway","volume":"301","author":"Yamamoto","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0400","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/ni986","article-title":"TRAM is specifically involved in the toll-like receptor 4-mediated MyD88-independent signaling pathway","volume":"4","author":"Yamamoto","year":"2003","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0405","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0006-8993(94)91908-9","article-title":"Behavioral effects of lipopolysaccharide in rats: Involvement of endogenous opioids","volume":"648","author":"Yirmiya","year":"1994","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0410","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger","year":"2014","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0415","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.cell.2011.09.051","article-title":"CD14 controls the LPS-induced endocytosis of toll-like receptor 4","volume":"147","author":"Zanoni","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0420","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1016\/j.bbamcr.2016.09.016","article-title":"Biased signalling is an essential feature of TLR4 in glioma cells","volume":"1863","author":"Zeuner","year":"2016","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2021.107918_bb0425","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1128\/IAI.73.5.2940-2950.2005","article-title":"Differential induction of the toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins","volume":"73","author":"Zughaier","year":"2005","journal-title":"Infection and Immunity"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821001200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821001200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:18:35Z","timestamp":1759011515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725821001200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":85,"alternative-id":["S0163725821001200"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107918","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TLR4 biased small molecule modulators","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107918"}}